MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413832 | Name: Disopyramide HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Disopyramide HCl is the salt form of Disopyramide, an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity.

Chemical Structure

Disopyramide HCl
Disopyramide HCl
CAS#54687-36-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 413832

Name: Disopyramide HCl

CAS#: 54687-36-4 (HCl)

Chemical Formula: C21H30ClN3O

Exact Mass: 375.2077

Molecular Weight: 375.94

Elemental Analysis: C, 67.09; H, 8.04; Cl, 9.43; N, 11.18; O, 4.26

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
3737-09-5 (free base) 22059-60-5 (phosphate) 54687-36-4 (HCl)
Synonym
Disopyramide HCl; Disopyramide hydrochloride
IUPAC/Chemical Name
alpha-(2-(Bis(1-methylethyl)amino)ethyl)-alpha-phenyl-2-pyridineacetamide hydrochloride
InChi Key
QFCSSPXLFBDRQQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H29N3O.ClH/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19;/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25);1H
SMILES Code
O=C(N)C(C1=CC=CC=C1)(CCN(C(C)C)C(C)C)C2=NC=CC=C2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 375.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Verlinden NJ, Coons JC. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Pharmacotherapy. 2015 Dec;35(12):1164-72. doi: 10.1002/phar.1664. Review. PubMed PMID: 26684556. 2: Isabelle le BL, Clarot F, Vaz E, Goullé JP, Proust B. Disopyramide and mianserin intoxication: a unique fatal case--review of the literature. J Forensic Sci. 2014 May;59(3):850-3. doi: 10.1111/1556-4029.12392. Epub 2014 Feb 6. Review. PubMed PMID: 24502246. 3: Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012 May-Jun;54(6):483-92. doi: 10.1016/j.pcad.2012.04.003. Review. PubMed PMID: 22687589. 4: Abe M, Maruyama T, Fujii Y, Kitai M, Okada K, Matsumoto K, Soma M. Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature. Clin Nephrol. 2011 Nov;76(5):401-6. Review. PubMed PMID: 22000561. 5: Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014 Jul;64(1):1-10. doi: 10.1016/j.jjcc.2014.02.022. Epub 2014 Apr 13. Review. Erratum in: J Cardiol. 2014 Oct;64(4):330. PubMed PMID: 24735741. 6: Sherrid MV. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev. 2016;12(1):52-65. Review. PubMed PMID: 26818487; PubMed Central PMCID: PMC4807719. 7: Siddoway LA, Woosley RL. Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet. 1986 May-Jun;11(3):214-22. Review. PubMed PMID: 3524956. 8: Brogden RN, Todd PA. Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs. 1987 Aug;34(2):151-87. Review. PubMed PMID: 3304965. 9: Morady F, Scheinman MM, Desai J. Disopyramide. Ann Intern Med. 1982 Mar;96(3):337-43. Review. PubMed PMID: 7036817. 10: Heel RC, Brogden RN, Speight TM, Avery GS. Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs. 1978 May;15(5):331-68. Review. PubMed PMID: 350555. 11: Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol. 2000 Sep;23(9):1433-5. Review. PubMed PMID: 11025903. 12: Taylor EH, Pappas AA. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. Ann Clin Lab Sci. 1986 Jul-Aug;16(4):289-95. Review. PubMed PMID: 2427003. 13: Kim SY, Benowitz NL. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Saf. 1990 Nov-Dec;5(6):393-420. Review. PubMed PMID: 2285495. 14: Karim A, Nissen C, Azarnoff DL. Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm. 1982 Oct;10(5):465-94. Review. PubMed PMID: 6762414. 15: Vaughan Williams EM. Disopyramide. Ann N Y Acad Sci. 1984;432:189-200. Review. PubMed PMID: 6395761. 16: Sathyavagiswaran L. Fatal disopyramide intoxication from suicidal/accidental overdose. J Forensic Sci. 1987 Nov;32(6):1813-8. Review. PubMed PMID: 3323413. 17: Barnay C. [Effects of disopyramide on normal and pathological atrioventricular conduction]. Ann Cardiol Angeiol (Paris). 1992 Oct;41(8):449-53. Review. French. PubMed PMID: 1298185. 18: Di Bianco R, Gottdiener JS, Singh SN, Fletcher RD. A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation. Angiology. 1987 Feb;38(2 Pt 2):174-83. Review. PubMed PMID: 3103491. 19: Wilson RR, Wallace AG. Disopyramide: six years' experience. Angiology. 1983 Jun;34(6):367-74. Review. PubMed PMID: 6346959. 20: Ankier SI, Carmichael DJ, Kidner PH. Disopyramide--a review. Scott Med J. 1977 Oct;22(4):314-9. Review. PubMed PMID: 337485.